TL;DR
The challenges of cascade genetic testing in hereditary cancer syndromes are discussed, addressing some of the ethical questions arising from its current model, from strategies aimed at improving its uptake, as well as from alternative approaches to identifying asymptomatic individuals who may carry a cancer- associated pathogenic variant.
AI-generated by Semantic Scholar
